

EPV1640

Transcranial Magnetic Stimulation in Bipolar Depression: retrospective analysis and literature review

C. P. Desport^{1*}, R. P. Andrade², C. Costa¹, C. Gomes¹, A. Dias¹, S. N. Martins¹, V. Covelo¹ and P. Valente¹

¹Psychiatry, Hospital de Magalhães Lemos, Unidade Local de Saúde de Santo António, Porto and ²Psychiatry, ULS Viseu Dão-Lafões, Viseu, Portugal

*Corresponding author.

doi: 10.1192/j.eurpsy.2025.2122

Introduction: Bipolar affective disorder (BD) affects approximately 2% of the population. It's an incapacitating condition that significantly impairs quality of life and functional capacity; depressive episodes in BD are highly debilitating and carry major suicide risk and treatment-resistant bipolar depression has been reported in about one-quarter of patients with bipolar disorders. Non-invasive neuromodulation procedures, such as repetitive transcranial magnetic stimulation (TMS), being an approved treatment for treatment-resistant unipolar depression, can also be an option for bipolar depression.

Objectives: with this work we intend to assess the efficacy and outcomes of the intermittent theta burst TMS (iTBS) protocol in patients with bipolar depression, who underwent this treatment at Hospital de Magalhães Lemos, Porto, since July 2022. We also conducted a literature review on the subject.

Methods: analysis of clinical and sociodemographic characteristics of the 4 patients who underwent treatment and of the treatment outcomes using Beck's Depression Inventory (BDI) score difference between first and last sessions and Montgomery-Asberg Depression Rating Scale (MADRS) as the secondary outcome, the last applied to only 2 of the patients. A computerized search was performed on PubMed, for articles published in the last 10 years, using the key-words "bipolar depression", "bipolar depressive episode" and "tms".

Results: since July 2022, 4 patients with bipolar depression were submitted to iTBS treatment, 3 women and 1 man. Of these, 3 had a diagnosis of bipolar type 1 disorder and 1 of bipolar type 2. One of the women had a comorbid diagnosis of dementia and was not able to answer BDI. All 4 of these patients were referred to this treatment after failure to reach sustained symptomatic remission with at least two different treatment trials, at adequate therapeutic doses. We found positive changes in BDI in all 3 patients that completed this questionnaire and in MADRS in the 2 that answered. One of the patients had an elevated mood and an increase in energy levels following treatment but did not meet criteria for hypomanic/manic episode. No major side effects were reported.

Conclusions: Our results and literature review suggest that TMS, in our study iTBS protocol, may well be an effective treatment for bipolar depression, with some studies showing even higher response rates for bipolar depression when compared with unipolar depression, suggesting that bipolar disorder is more likely a better biological target. Furthermore, the low side effect profile of TMS and the fact that it is a minimally invasive procedure, makes it even more appealing as a treatment option. Risk of psychomotor agitation and hypomania/mania must be closely monitored in these cases.

Disclosure of Interest: None Declared

EPV1642

Effectiveness of Electroconvulsive Therapy in Postpartum Psychosis: A Systematic Review

O. Herrera-Barrón^{1*}, X. Cors-Cepeda¹, C. López-García¹ and J. Paez-Mayorga¹

¹School of Medicine and Health Sciences at Tecnológico de Monterrey, Monterrey, Mexico

*Corresponding author.

doi: 10.1192/j.eurpsy.2025.2123

Introduction: Postpartum psychosis (PPP) is a psychiatric condition that arises shortly after childbirth. Electroconvulsive therapy (ECT) offers rapid symptom relief, particularly in severe cases. Despite reports of ECT effectiveness in PPP, its use remains limited and unstandardized.

Objectives: This systematic review aims to evaluate the clinical effectiveness of ECT in treating PPP.

Methods: The electronic databases PubMed/MEDLINE, Cochrane, SciELO, SCOPUS, and WOS were screened for studies reporting ECT outcomes in PPP following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies published between 2004 and 2024, written in English, and focused on subjects up to 12 months postpartum were included. All studies were vetted by ≥ 2 reviewers. Bias was assessed with the JBI Critical Appraisal Tool.

Results: A total of 255 studies were identified and 7 met the inclusion criteria. ECT was exclusively used in severe PPP refractory to pharmacological intervention. Symptom improvement was reported in 100% of cases and most achieved total remission. Total ECT sessions ranged from 5 to 15, with symptom improvement after 1-6 sessions and remission after 5-11 sessions. ECT side effects were transient and included memory loss, mild cognitive deficit, and pain.

Conclusions: High remission rates on ECT were demonstrated where pharmacological intervention was insufficient, highlighting its effectiveness as a rapid and safe intervention for PPP. Adverse effects were transient and manageable, underscoring ECT safety. Small sample sizes and variability in ECT protocols limit the generalizability of the findings. Further evidence from prospective studies is needed to consider ECT as a first line treatment for PPP.

Disclosure of Interest: None Declared

EPV1643

Deep brain stimulation for obsessive-compulsive disorder : A look back over 24 years of use

A. Karmous^{1*}, H. Ghabi², A. Hajri¹, E. Khelifa¹, A. Maamri¹ and H. Zalila¹

¹Emergency and outpatient department and ²Department G, Razi hospital, Manouba, Tunisia

*Corresponding author.

doi: 10.1192/j.eurpsy.2025.2124

Introduction: Deep brain stimulation (DBS) was first used in 1999 for the treatment of resistant obsessive-compulsive disorder (OCD), and it was not until 2009 that the Food and Drug Administration approved it for this purpose.